Skip to main content
. 2015 Jan 24;6(4):1967–1980. doi: 10.18632/oncotarget.2806

Figure 1. Hypoxia blocks lapatinib-mediated effects in ERBB2-positive breast cancer cells.

Figure 1

(A) Indicated cells were treated with 1 μM lapatinib under hypoxia for 48h and cell viability was assessed by MTS assay. (B) MCF10A-ERBB2 cells were treated with increasing doses of lapatinib under normoxic or hypoxic conditions and cell viability was assessed. (C) Cell were placed in 3D culture conditions and transferred to normoxic or hypoxic conditions in the presence or absence of lapatinib. Cells were then stained for cleaved caspase-3 (top) and the percentage of caspase-positive acini was determined (bottom). (D) Cell lysates were collected from cells in B for immunoblot analysis. Error bars indicate S.E. (*p ≤ 0.05).